| Cat.No. | Name | Information |
|---|---|---|
| M3030 | S-Ruxolitinib | S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
| M1820 | Tofacitinib | Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM. |
| M1660 | AZ 960 | AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro. |
| M1646 | AG490 | AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). |
| M1733 | TG101348 | TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM. |
| M1787 | INCB18424 | Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo. |
| M5944 | Ruxolitinib phosphate | Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
| M3616 | Tofacitinib citrate | Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. |
| M2346 | Filgotinib | Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively. |
| M2044 | AZD1480 | AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively. |
| M49568 | JAK 3i | JAK3i is a highly selective JAK3 inhibitor (IC50: 0.43 nM). |
| M49567 | Ivarmacitinib sulfate | Ivarmacitinib (SHR0302) sulfate is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. |
| M49566 | Itacnosertib | Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871. |
| M49563 | GDC-4379 | GDC-4379 is a JAK1 inhibitor that can be used for the research of asthma. |
| M49562 | DPPY | DPPY is a potent PTK inhibitor with IC50 values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. |
| M49561 | AZ-3 | AZ-3 is a potent and selective JAK1 inhibitor with an IC50 of 34 nM. |
| M49560 | Axltide | Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). |
| M49559 | AT9283 lactic acid | AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). |
| M49558 | Antitumor agent-123 | Antitumor agent-123 effectively inhibits multiple kinase targets with anti-cancer effects, including JAK2, JAK3, HDAC1 and HDAC6, with IC50 values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. |
| M49556 | 25-Deacetylcucurbitacin A | 25-Deacetylcucurbitacin A is a Cucurbitane-Type triterpenoid and has the potential to be an anti-cancer agent and JAK/STAT3 signaling pathway inhibitor. |
| M49555 | JAK-IN-11 | JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment. |
| M49554 | Lorpucitinib | Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease. |
| M49553 | JAK2 JH2 binder-1 | JAK2 JH2 binder-1 is a potent and selective JAK2 JH2 binder, with a Kd of 37.1 nM. |
| M49552 | Povorcitinib phosphate | Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. |
| M49551 | JAK-IN-5 hydrochloride | JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. |
| M49550 | JAK-IN-23 | JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. |
| M49549 | GS-829845 | GS-829845 is a major, active metabolite of Filgotinib. |
| M49548 | VVD-118313 | VVD-118313 is a potent, selective JAK1 inhibitor. |
| M49547 | Pumecitinib | Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity. |
| M43416 | SJ1008030 TFA | SJ1008030 TFA is a JAK2 PROTAC which selectively degrades JAK2. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
